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Kratom (Mitragyna speciosa Korth., Rubiaceae) is native to and has traditional use in
Southeast Asia. The number of kratom users outside of Southeast Asia has increased
significantly in recent decades with use spreading to the Unites States (US) and Europe.
Because of its reputed opioid-like psychoactive effects at higher doses, kratom has
been regulated in several countries and is subject to an import ban by the US Food
and Drug Administration. Nonetheless, in the US it is estimated that 10–15 million
people consume kratom primarily for the self-treatment of pain, psychiatric disorders, to
mitigate withdrawal from or dependence on opioids, and to self-treat opioid use disorder
or other substance use disorders (SUDs). Due to the global COVID-19 pandemic, a
shortage in the supply of kratom products may place unexpected burdens on kratom
users, potentially influencing some who use kratom for SUD self-treatment to regress
to harmful drug use, hence increasing the likelihood of adverse outcomes, including
overdose. Inadequate treatment, treatment barriers, and increases in the sales of
adulterated kratom products on the internet or in convenience stores could exacerbate
circumstances further. Although there are currently no verified indications of kratom
scarcity, researchers and clinicians should be aware of and remain vigilant to this
unanticipated possibility.
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INTRODUCTION
Kratom (Mitragyna speciosa Korth., Rubiaceae) is a tree native to
Southeast Asia with psychoactive properties due to the presence
of indole alkaloids (1, 2). The primary alkaloid, mitragynine,
has been shown to interact with µ-opioid receptors as a biased
partial agonist leading to analgesia (3). In addition, kratom
products may also produce dose- and strain-dependent stimulant
and sedative effects (4). Chronic consumption at high doses
has a potential to cause dependence and withdrawal symptoms
(5) consistent with a Substance Use Disorder (SUD) (6, 7). A
majority of user surveys and numerous observational studies
suggest that kratom is widely used in Western nations for
a range of conditions, including self-treatment of acute and
chronic pain, psychiatric conditions, such as depressive and
anxiety disorders, and mitigation of withdrawal symptoms from
addictive drugs, both illicit and prescribed, particularly opioid-
based medications (8). Among polydrug users and those with
a history of SUD, kratom has also been consumed as a means
of reducing use of or abstaining from dangerous prescription
opioids and heroin (9, 10). Adverse effects of kratom use have
been reported in several cases of polydrug use with opioids,
benzodiazepines, and acetaminophen primarily resulting in
seizures, hepatotoxicity, and gastrointestinal symptoms (11).
Polydrug exposure involving kratom increases the odds ratio
of more serious adverse events occurring, including admittance
to a healthcare facility and occurrence of more serious medical
outcomes such as hepatic damage and death (12, 13). Kratom
withdrawal symptoms are similar to those of opioids but with
lower severity, presenting with transient gastrointestinal upset,
muscle and nerve pain, insomnia, sweating, tremor, fatigue,
and psychological distress including restlessness, irritability,
increased cravings, depressed mood, and anxiety. Buprenorphine
in combination with clonidine may prove to be a clinically
effective treatment for most of these symptoms as indicated
by case reports, although these drugs are associated with
their own adverse effects (5). However, in traditional settings,
kratom users have their own methods for mitigating kratom
withdrawal symptoms.
The widespread use of kratom and consistent reports of
its benefits or therapeutic value that are important to users
raises the question: would sudden decreases in the availability
of the plant have negative impacts on kratom users? Various
internet studies found that some kratom users are concerned
about the possibility of relapsing to opioids and/or seeking
alternative, possibly questionable, sources of kratom if products
become less readily available. This is a serious concern as
kratom, not currently regulated as a dietary supplement, may be
adulterated by unscrupulous traders and cause users to relapse
to opioid use and inevitably experience a significant increase
in overdose risk (7, 9, 14–17). Indeed, there is evidence to
suggest that the COVID-19 pandemic has been associated with
increased drug overdose deaths and that the reduced access
to conventional treatment, as well as mutual-aid groups, is a
plausible contributing factor (18), though it is unknown whether
diminished access to kratom has explicitly contributed to any
overdose deaths.
Possible Kratom Scarcity and Misuse in
the Context of COVID-19
Because of the potential public health impact of kratom
scarcity and the international implications of COVID-19,
the probable impact of the global pandemic on kratom
availability is of significant interest in regard to consumption
patterns. Specifically, COVID-19-related disruptions in kratom
access/supply and use could increase the likelihood that users
turn to more readily available, but more dangerous, products to
self-treat symptoms they had primarily used kratom for. Even
prior to the pandemic, the kratom supply chain experienced
significant, repeated disruptions and episodes of consumer
uncertainty. This was at least partially due to the import alert
issued by FDA in February 2014 which resulted in companies
restricting inventory to avoid FDA seizure (19). Another concern
that COVID-19 raises in addition to potential supply chain
disruptions is the possibility that people may use or misuse
kratom in an attempt to inoculate themselves from COVID-19
infection or to self-treat the various symptoms associated with
COVID-19, despite no scientific support for kratom use in such
a manner (20, 21).
Origin of Anecdotal Accounts
Although the obtained information is anecdotal, we were able
to solicit informal accounts from kratom growers in Malaysia
and vendors in the United States (Arizona, Florida, and Illinois)
and Europe. Kratom users also provided us with information
on the state of kratom supply and personal consumption. Due
to the fast-moving nature of COVID-19, we relied on informal,
personal networks and publicly advertised vendors to compile a
sense of the situation over a period of 3 months between March
and May 2020, rather than undertake a systematic study of a
continually evolving situation. We believe that these anecdotal
accounts will help researchers identify key areas of focus in the
coming year.
DISCUSSION
Kratom Growers and Vendors
Using community and personal contacts, we were alerted to
several important factors that warrant investigation. First, due
to shelter-in-place orders and social distancing restrictions,
kratom growers in Malaysia experienced problems selling their
harvest. Further, the initial rigid phase of the movement control
order disrupted distribution of kratom supply from kratom
plantations to consumers, chiefly among those who have been
using kratom to self-treat SUDs. Disrupted trade routes via
sea or air have been reported for some kratom products,
although it is unknown to what degree this has impacted global
kratom supply to date. Kratom vendors in the US and Europe,
despite the imposed import bans, primarily obtain their kratom
supplies from Indonesia which is the main global exporter for
kratom (22). The majority of vendors have not seen changes
in supplies of kratom products since December 2019 although
they expressed uncertainty as to whether that may change in
the future if COVID-19 leads to the imposition of additional
commercial restrictions. In response to the uncertainty of the
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kratom market, many vendors have increased their stock supply
in recent months in preparation for potential pandemic-related
disruptions. Distributors who obtain a majority of their kratom
product from Thailand were able to continue typical purchasing
levels until February 2020, which resulted in a stockpile due
to shop closures related to mandated lock-downs and social
distancing. Vendors are expecting a resumption in purchasing
now that some shops are reopening, and anticipate a return
to typical sales volume. Though kratom vendors noticed an
increased demand for kratom products among users in recent
months, they did not perceive that the increase was associated
with a novel indication or different uses of kratom. At least
one vendor associated the increased demand with the Netflix
production “A Leaf of Faith” (released 2018 but still available on
Netflix), having several new customers mention their decision to
try kratom as a result of having watched the documentary, rather
than COVID-19 related issues.
Kratom Users
Given disruptions described above, kratom users in Malaysia
encountered problems obtaining their regular kratom supply.
The problem worsened when enforcement agencies raided illegal
kratom ports in the community—making it more difficult for
opioid users and people with SUDs who were self-treating
their dependence with kratom to obtain their regular supply.
Similarly, due to COVID-19, manual laborers who were daily
wage earners lost their income and could not afford kratom
products to self-treat medical conditions. Most US kratom users
did not discuss difficulties with obtaining kratom products from
their usual sources since the outbreak of COVID-19 in their
respective locality. Still, users were cognizant of the possibility of
kratom shortages if the pandemic continues. Many users feared
that they may not have access to their usual products for the
rest of the year. To date, this fear has not resulted in users
stockpiling kratom, likely due to limited affordability (e.g., most
people could not afford to hoard kratom like other, less expensive
commodities). Few users mentioned increasing their kratom
consumption during COVID-19. Reasons for use primarily
centered on alleviating stress or psychiatric disorder symptoms
(e.g., anxiety and depression), or continuation of kratom as a
means of addressing SUD symptoms. Given the limited number
of kratom users informally consulted (n = 42), these anecdotes
cannot be generalized. Of concern, some sources have noted
increases in unscientific claims made by irresponsible vendors
regarding kratom’s supposed “anti-coronavirus” properties (23).
The FDA is issuing warnings to such disreputable vendors and
kratom advocacy organizations are condemning misinformation
through consumer advisory postings, though the degree to which
this misinformation is spreading to users remains unclear and if
it differs by nation (21, 23).
Potential Implications of COVID-19 on
Kratom Availability and Use
Our on-the-ground conversations provided an outlook of how
kratom growers, vendors, and users perceive COVID-19 and its
impact, providing a starting point for systematic investigation.
According to published user surveys, common reasons for
kratom use include the self-treatment of acute and chronic
pain, psychological distress, mitigation of dependence and/or
withdrawal symptoms from an illicit or prescription drug use
(7, 9, 15). While the ongoing pandemic has created uncertainty
among vendors and users about kratom availability, it has not,
to date, impacted the actual availability of the product in the
US. Considering the potential importance of kratom as a self-
treatment strategy or harm-reduction component for SUDs, an
unanticipated supply disruption may lead to a rise in opioid and
other drug use with subsequently increased risk for overdose and
fatality. Reduced kratom access may also negatively impact the
well-being of individuals who use kratom for the acute relief
of psychological distress at a time of increasing socioeconomic
uncertainty and stress. COVID-19-related disruptions in kratom
availability may also influence or coerce regular users to try
more harmful herbal, synthetic, or plant-based New Psychoactive
Substances or even illicit drugs in self-managing their aggravating
health conditions (24). In an unexpected situation, if there is
an imminent increase in kratom fatalities/toxicities arising from
the COVID-19 pandemic, enforcement agencies may use the
scenario as a precedent to legally or effectively ban kratom use.
Based on import and sales of kratom, there are an estimated
10–15 million kratom users in the US, meaning that disruptions
for even a small proportion of regular users could result in
an outsized effect (25). In the coming months, it will be
important to monitor kratom supplies and purchasing avenues
(e.g., Internet and local shops). The Internet will likely be an
increasingmethod formonitoring sales, user reaction to COVID-
19, issues related to supply, and motivations for use during the
pandemic. It will also be important to raise awareness among
healthcare professionals if current kratom users circumstantially
experience shortages. In such cases, regular kratom users may
come to the clinical attention of healthcare professionals, possibly
requiring prescribed treatment options in the absence of kratom
(e.g., anxiolytics, antidepressants, analgesics, and opioid agonist
therapies). Further information is also needed to improve our
understanding on how the impact of COVID-19 is affecting
kratom users in terms of obtaining unadulterated kratom
products, as well as other important occurrences that could affect
kratom supply, patterns of use and its therapeutic popularity
among users.
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